“Harbinger Health is poised to redefine our approach to oncology, moving beyond cancer 'staging' and toward early detection that enables the diagnosis and treatment of cancer and ultimately to effectively reduce morbidity and mortality associated with the disease,” Hahn said in a prepared statement. “We are committed to developing our platform so there is access to early cancer detection for all individuals with a simple test. No one should be disadvantaged in the fight against cancer—it's our goal to bring the power of this platform not only to those with access to the top cancer centers—but to everyone.”

“Harbinger Health has the potential to revolutionize the way we detect, diagnose, and treat cancer, enabling interventions at a much earlier phase of the disease than is currently possible,” added Doug Cole, MD, co-founder and chairman of Harbinger Health and a managing partner at Flagship Pioneering. “Unlike prior approaches that are purely statistical in nature, Harbinger's approach is informed by its insights into specific biological events that take place early in the development of cancer.”